Published in Semin Radiat Oncol on July 01, 2012
Epidemiology of oral human papillomavirus infection. Oral Oncol (2013) 1.07
The economic burden of head and neck cancer: a systematic literature review. Pharmacoeconomics (2014) 0.82
Induction of heparanase by HPV E6 oncogene in head and neck squamous cell carcinoma. J Cell Mol Med (2013) 0.81
Do 18F-FDG PET/CT parameters in oropharyngeal and oral cavity squamous cell carcinomas indicate HPV status? Clin Nucl Med (2015) 0.80
Oral Cavity and Oropharyngeal Cancer: Changing Trends in Incidence in the United States and Oklahoma. J Okla State Med Assoc (2016) 0.75
Assessing p16 Status of Oropharyngeal Squamous Cell Carcinoma by Combined Assessment of the Number of Cells Stained and the Confluence of p16 Staining: A Validation by Clinical Outcomes. Am J Surg Pathol (2016) 0.75
High-risk HPV genotypes and P16INK4a expression in a cohort of head and neck squamous cell carcinoma patients in Singapore. Oncotarget (2016) 0.75
Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med (2010) 22.74
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell (1990) 20.60
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science (1989) 16.54
Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med (2007) 16.39
Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst (2000) 14.43
Classification of papillomaviruses. Virology (2004) 14.16
The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell (1993) 12.41
Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol (2011) 12.10
Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem (1999) 11.87
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev (2005) 9.47
Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst (2008) 8.70
Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol (2008) 7.97
Head and neck cancer. N Engl J Med (2001) 7.32
Association of cancer with AIDS-related immunosuppression in adults. JAMA (2001) 6.80
EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol (2008) 5.46
A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J (1991) 5.39
Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell (1999) 4.94
Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol (2010) 4.39
Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol (2009) 3.70
Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. Clin Cancer Res (2003) 3.42
Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. Proc Natl Acad Sci U S A (1997) 3.37
Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci U S A (1993) 3.32
Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res (2007) 2.93
Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol (2006) 2.91
The cannabinoid system and immune modulation. J Leukoc Biol (2003) 2.87
Binding of human virus oncoproteins to hDlg/SAP97, a mammalian homolog of the Drosophila discs large tumor suppressor protein. Proc Natl Acad Sci U S A (1997) 2.87
PIK3CA as an oncogene in cervical cancer. Oncogene (2000) 2.75
Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol (2009) 2.74
Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res (2003) 2.70
Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol (2004) 2.59
Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res (2009) 2.51
Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol (2011) 2.47
E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst (2009) 2.45
Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci U S A (1996) 2.30
Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res (2006) 2.05
Inhibition of transfer to secondary receptors by heparan sulfate-binding drug or antibody induces noninfectious uptake of human papillomavirus. J Virol (2007) 1.96
Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annu Rev Pathol (2009) 1.88
Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. Arch Otolaryngol Head Neck Surg (2009) 1.80
Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene (1998) 1.78
Human papillomaviruses bind a basal extracellular matrix component secreted by keratinocytes which is distinct from a membrane-associated receptor. Virology (2005) 1.73
Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor. J Virol (2007) 1.73
TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol (2007) 1.70
Cell-surface heparan sulfate proteoglycans: dynamic molecules mediating ligand catabolism. Curr Opin Lipidol (1997) 1.53
Sequential activation of cyclin E and cyclin A gene expression by human papillomavirus type 16 E7 through sequences necessary for transformation. J Virol (1995) 1.52
Human papillomavirus seropositivity and risks of head and neck cancer. Int J Cancer (2007) 1.39
HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiother Oncol (2009) 1.28
Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes. PLoS One (2011) 1.26
Identification of ZASC1 encoding a Krüppel-like zinc finger protein as a novel target for 3q26 amplification in esophageal squamous cell carcinomas. Cancer Res (2003) 1.25
Role of Rb-dependent and Rb-independent functions of papillomavirus E7 oncogene in head and neck cancer. Cancer Res (2007) 1.13
HPV-induced oropharyngeal cancer, immune response and response to therapy. Cancer Lett (2009) 1.13
Emerging theme: cellular PDZ proteins as common targets of pathogenic viruses. J Virol (2011) 1.12
The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongue. Clin Cancer Res (2003) 1.11
The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial. Radiother Oncol (2011) 1.10
Hypoxia in head and neck cancer: studies with hypoxic positron emission tomography imaging and hypoxic cytotoxins. Int J Radiat Oncol Biol Phys (2007) 1.04
Immortalization of oral keratinocytes by functional inactivation of the p53 and pRb pathways. Int J Cancer (2010) 0.97
Act globally, think locally: systems biology addresses the PDZ domain. ACS Chem Biol (2006) 0.94
Papillomavirus virus-like particles as vehicles for the delivery of epitopes or genes. Arch Virol (2006) 0.93
Chemo-radiotherapy in patients with locally advanced nasopharyngeal carcinoma: a radiation therapy oncology group study. J Clin Oncol (1990) 0.90
Head and neck squamous cell carcinomas in HIV-positive patients: a preliminary investigation of viral associations. Head Neck Pathol (2010) 0.89
Clinically significant human papilloma virus in squamous cell carcinoma of the head and neck in UK practice. Clin Oncol (R Coll Radiol) (2011) 0.89
Aerodigestive cancers in HIV infection. Curr Opin Oncol (2005) 0.84
Therapeutic targets in head and neck squamous cell carcinoma: identification, evaluation, and clinical translation. Oral Oncol (2011) 0.84
Nasopharynx carcinoma: choice of treatment. Int J Radiat Oncol Biol Phys (1995) 0.82
Marijuana use is not associated with cervical human papillomavirus natural history or cervical neoplasia in HIV-seropositive or HIV-seronegative women. Cancer Epidemiol Biomarkers Prev (2010) 0.76
Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med (2010) 22.74
Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol (2012) 3.04
A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn (2010) 2.86
Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res (2006) 2.05
Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res (2012) 2.02
Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol Cell Biol (2008) 1.95
Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS One (2010) 1.77
Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer. J Clin Invest (2009) 1.68
A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma. Oral Oncol (2013) 1.57
Comparative shotgun proteomics using spectral count data and quasi-likelihood modeling. J Proteome Res (2010) 1.43
A feed-forward loop involving protein kinase Calpha and microRNAs regulates tumor cell cycle. Cancer Res (2009) 1.43
Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J Oncol (2010) 1.40
Epithelial tissues have varying degrees of susceptibility to Kras(G12D)-initiated tumorigenesis in a mouse model. PLoS One (2011) 1.38
Activation of the NOTCH pathway in head and neck cancer. Cancer Res (2013) 1.15
Human papillomavirus in early laryngeal carcinoma. Laryngoscope (2009) 1.10
Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03. J Clin Oncol (2009) 1.00
The twist box domain is required for Twist1-induced prostate cancer metastasis. Mol Cancer Res (2013) 0.97
Phase 2 trial of oxaliplatin and pemetrexed as an induction regimen in locally advanced head and neck cancer. Cancer (2011) 0.96
Evolution of clinical trials in head and neck cancer. Crit Rev Oncol Hematol (2008) 0.95
Proteomic analysis of oropharyngeal carcinomas reveals novel HPV-associated biological pathways. Int J Cancer (2012) 0.94
Opportunities and challenges in the era of molecularly targeted agents and radiation therapy. J Natl Cancer Inst (2013) 0.93
A retrospective analysis of cross-reacting cetuximab IgE antibody and its association with severe infusion reactions. Cancer Med (2014) 0.92
Loss of Trop2 promotes carcinogenesis and features of epithelial to mesenchymal transition in squamous cell carcinoma. Mol Cancer Res (2011) 0.91
Gene expression signatures modulated by epidermal growth factor receptor activation and their relationship to cetuximab resistance in head and neck squamous cell carcinoma. BMC Genomics (2012) 0.91
Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma. Expert Rev Anticancer Ther (2012) 0.91
Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy. Mol Cancer Ther (2012) 0.90
New promising molecular targets in head and neck squamous cell carcinoma. Curr Opin Oncol (2012) 0.90
Dual blockade of the EGFR and COX-2 pathways: a phase II trial of cetuximab and celecoxib in patients with chemotherapy refractory metastatic colorectal cancer. Am J Clin Oncol (2011) 0.89
Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck. Cancer (2008) 0.89
Reliability and validity of the Vanderbilt Head and Neck Symptom Survey: a tool to assess symptom burden in patients treated with chemoradiation. Head Neck (2010) 0.89
Retrospective review of positron emission tomography with contrast-enhanced computed tomography in the posttreatment setting in human papillomavirus-associated oropharyngeal carcinoma. Arch Otolaryngol Head Neck Surg (2012) 0.87
Hypothyroidism as a consequence of intensity-modulated radiotherapy with concurrent taxane-based chemotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys (2009) 0.85
Update on molecular diagnostic tests in head and neck cancer. Semin Oncol (2008) 0.84
Predicting survival in head and neck squamous cell carcinoma from TP53 mutation. Hum Genet (2014) 0.84
Therapeutic targets in head and neck squamous cell carcinoma: identification, evaluation, and clinical translation. Oral Oncol (2011) 0.84
Prognostic value of FDG PET metabolic tumor volume in human papillomavirus-positive stage III and IV oropharyngeal squamous cell carcinoma. AJR Am J Roentgenol (2014) 0.83
Preferential activation of the hedgehog pathway by epigenetic modulations in HPV negative HNSCC identified with meta-pathway analysis. PLoS One (2013) 0.83
Nuclear epidermal growth factor receptor and p16 expression in head and neck squamous cell carcinoma. Laryngoscope (2012) 0.81
Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma. Cancer Biol Ther (2015) 0.81
FDG volumetric parameters and survival outcomes after definitive chemoradiotherapy in patients with recurrent head and neck squamous cell carcinoma. AJR Am J Roentgenol (2014) 0.81
Notch signaling mediates melanoma-endothelial cell communication and melanoma cell migration. Pigment Cell Melanoma Res (2013) 0.78
Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. BMC Cancer (2014) 0.77
Analysis of microsatellite mutations in buccal cells from a case-control study for lung cancer. Cancer Epidemiol (2011) 0.75
p16 Expression as a predictive biomarker of hypoxic cell-sensitizing agents in oropharyngeal cancer. J Clin Oncol (2010) 0.75
Implications of the New Face of Head and Neck Cancer. Oncology (Williston Park) (2015) 0.75